Specific imaging of immune cell dynamics using novel tracer strategies
Ongoing | IMI2 |
Immune-image logo


Start Date
End Date
IMI2 - Call 14
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
15 000 000
EFPIA in kind
12 154 527
46 274
Total Cost
27 200 801


Immunotherapies, which harness the immune system to fight disease, are revolutionising the treatment of many cancers and inflammatory diseases. However, while these innovative treatments prove life-saving for some patients, others do not respond to immunotherapies at all, and others experience serious side effects. The Immune-Image project aims to pioneer the use of non-invasive imaging technologies to track the activity of immune cells in the body. Ultimately, the project will make it easier to predict how patients will respond to treatment and monitor their progress during treatment.

To do this, the project will develop tracers capable of highlighting specific immune cells in a range of imaging types, including magnetic resonance imaging (MRI), positron emission tomography (PET), optical imaging (OI) and computed tomography (CT). They will also analyse biopsies and blood samples to build up complete immunological profiles of patients and to correlate imaging findings with pathology; this information will contribute to the development of personalised immunotherapies.

Participants Show participants on map

EFPIA companies
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Imaginab, Inc, Inglewood Ca, United States
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Novartis Pharma AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France
  • Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany
  • Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain
  • Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron (Vhio), Barcelona, Spain
  • Stichting Vumc, Amsterdam, Netherlands
  • University of Cambridge, Cambridge, United Kingdom
  • Vib Vzw, Zwijnaarde - Gent, Belgium
  • Vrije Universiteit Brussel, Brussel, Belgium
  • Westfaelische Wilhelms-Universitaet Muenster, Münster, Germany
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Antaros Medical AB, Mölndal, Sweden
  • Lawrencium Legal BV, Amsterdam, Netherlands
  • Stichting Lygature, Utrecht, Netherlands
  • Ttopstart BV, Bilthoven, Netherlands
Patient organisations
  • European Cancer Patient Coalition, Brussels, Belgium
Third parties
  • Cloudselling BV, Rijswijk, Netherlands
  • Universite Paris-Saclay, Saint Aubin, France
Project coordinator
Albert D Windhorst
Stichting Vumc